Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737

被引：30

作者：

Ishitsuka, Kenji ^{[1
]}

Kunami, Naoko ^{[1
]}

Katsuya, Hiroo ^{[1
]}

Nogami, Rumiko ^{[1
]}

Ishikawa, Chie ^{[2
,3
]}

Yotsumoto, Fusanori ^{[4
]}

Tanji, Hiroe ^{[2
]}

Mori, Naoki ^{[2
]}

Takeshita, Morishige ^{[5
]}

Miyamoto, Shingo ^{[6
]}

Tamura, Kazuo ^{[1
]}

机构：

[1] Fukuoka Univ, Dept Internal Med, Div Med Oncol Hematol & Infect Dis, Fukuoka 8140180, Japan

[2] Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan

[3] Univ Ryukyus, Transdisciplinary Res Org Subtrop & Isl Studies, Nishihara, Okinawa 9030215, Japan

[4] Fukuoka Univ, Sch Med, Dept Biochem, Fukuoka 8140180, Japan

[5] Fukuoka Univ, Sch Med, Dept Pathol, Fukuoka 8140180, Japan

[6] Fukuoka Univ, Dept Obstet & Gynecol, Fukuoka 8140180, Japan

来源：

CANCER LETTERS | 2012年 / 317卷 / 02期

关键词：

ATLL; Novel treatment; Bcl-2 family proteins; Apoptosis; ABT-737; ACUTE LYMPHOBLASTIC-LEUKEMIA; MULTIPLE-MYELOMA CELLS; BH3 MIMETIC ABT-737; NF-KAPPA-B; CONSTITUTIVE ACTIVATION; DOWN-REGULATION; X-L; APOPTOSIS; LYMPHOMA; SENSITIVITY;

D O I：

10.1016/j.canlet.2011.11.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-lymphotropic virus type 1 (HTLV-1). ABT-737, a small molecule inhibitor of Bcl-2, Bcl-X-L, and Bcl-w, significantly induced apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells, and synergistically enhanced the cytotoxicity and apoptosis induced by conventional cytotoxic drugs. Moreover, ABT-737 significantly inhibited the in vivo tumor growth of an ATLL mouse model. These results suggest that the use of an agent targeting anti-apoptotic bcl-2 family proteins, either alone or in combination with other conventional drugs, represents a novel promising approach for ATLL (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：218 / 225

页数：8

共 50 条

[41] Bcl-2 family proteins
John C Reed
Oncogene, 1998, 17 : 3225 - 3236
[42] The bcl-2 family of proteins
Brown, R
BRITISH MEDICAL BULLETIN, 1997, 53 (03) : 466 - 477
[43] ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
Ji-Yu Li
Yu-Yang Li
Wei Jin
Qing Yang
Zhi-Ming Shao
Xing-Song Tian
Journal of Experimental & Clinical Cancer Research, 31
[44] Identification of vulnerabilities for targeting BCL-2 family members in T-Cell Acute Lymphoblastic Leukemia
Fortner, Colin
Wichert, Maren
Niedermayer, Alexandra
Debatin, Klaus-Michael
Meyer, Lueder Hinrich
Seyfried, Felix
BLOOD, 2023, 142
[45] ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
Li, Ji-Yu
Li, Yu-Yang
Jin, Wei
Yang, Qing
Shao, Zhi-Ming
Tian, Xing-Song
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
[46] Blockade of Bcl-2 Family Apoptosis Inhibitors Using ABT-737 (ABT-263 Analog) Potentiate CAR T Cells
Karlsson, Hannah S. C.
Lindqvist, Camilla A.
Fransson, Moa
Nilsson, Berith
Essand, Magnus
Nilsson, Kenneth
Wiklund, Helena Jemberg
Frisk, Per
Loskog, Angelica S. I.
MOLECULAR THERAPY, 2012, 20 : S183 - S183
[47] Effective cell killing of primary acute lymphoblastic leukemia cells by the BCL-2 antagonist ABT-737
Tafuri, A.
Ricciardi, M. R.
Gregorj, C.
De Cave, F.
Santinelli, S.
Bergamo, P.
Decandia, S.
Vitale, A.
Petrucci, M. T.
Milella, M.
Foa, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 5 - 6
[48] BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
Beurlet, Stephanie
Omidvar, Nader
Gorombei, Petra
Krief, Patricia
Le Pogam, Carole
Setterblad, Niclas
de la Grange, Pierre
Leboeuf, Christophe
Janin, Anne
Noguera, Maria-Elena
Hervatin, Florence
Sarda-Mantel, Laure
Konopleva, Marina
Andreeff, Michael
Tu, Andrea W.
Fan, Alice C.
Felsher, Dean W.
Whetton, Anthony
Pla, Marika
West, Robert
Fenaux, Pierre
Chomienne, Christine
Padua, Rose Ann
BLOOD, 2013, 122 (16) : 2864 - 2876
[49] The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Trudel, Suzanne
Stewart, A. Keith
Li, Zhihua
Shu, Yanjun
Liang, Sheng-Ben
Trieu, Young
Reece, Donna
Paterson, Josh
Wang, Dingyan
Wen, Xiao-Yan
CLINICAL CANCER RESEARCH, 2007, 13 (02) : 621 - 629
[50] Functional effects of the Bcl-2/Bcl-xL inhibitor ABT-737 on primary cells from smoldering multiple myeloma
Ricciardi, Maria Rosaria
Calabrese, Elisabetta
De Cave, Fabiana
Santinelli, Sara
Bergamo, Paola
Decandia, Samantha
Gregorj, Chiara
Federico, Vincenzo
Milella, Michele
Foa, Robert
Tafuri, Agostino
Petrucci, Maria Teresa
BLOOD, 2007, 110 (11) : 269B - 269B

← 1 2 3 4 5 →